August 27, 2021
Early Sales of Biogen’s Alzheimer Drug Remain Unclear
By: Josh Nathan-Kazis
In a Wednesday note, Piper Sandler analyst Christopher Raymond cut his estimate for near-term sales, saying that an August survey of neurologists who treat Alzheimer’s disease showed a downward shift in their projections of Aduhelm’s use.
The survey, conducted by the market research group Spherix Global Insights, polled 74 neurologists. The results, Raymond wrote, show that “the near-constant stream of negative Aduhelm headlines has impacted sentiment and near-term expectations for uptake…” (read more)